Commitee for Advanced Therapy Medicinal Products (CAT) - Public Call for Expression of Interest

The European Commission and the EMA published a Public Call for Expression of Interest as representative of Patients' Associates and Clinicians to the Commitee for Advanced Therapy Medicinal Products (CAT) of the European Medicines Agency.

Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products1 ("the Regulation") lays down specific rules concerning the authorisation, supervision and pharmacovigilance of advanced therapy medicinal products (gene therapy, somatic cell therapy and tissue engineering). Central to the operation of this Regulation is the Committee for Advanced Therapies (CAT) established as part of the EMA.

The members of the CAT are appointed for a renewable period of three years. The three year term of the current members started on January 2009 and this call is intended to select candidates to replace them. Current members may reapply.

The CAT is composed of:

• five members or co-opted members of the Committee for Medicinal Products for Human Use (CHMP), with their alternates. These members are appointed by the CHMP itself;
• one member and one alternate appointed by each European Union (EU) Member State that is not represented by the members and alternates appointed by the CHMP;
• two members and two alternates appointed by the European Commission to represent clinicians;
• two members and two alternates appointed by the European Commission to represent patient associations.

Get more details about the CAT on the EMA website - CAT: Overview.